Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioLineRx stock | $2.92

Own BioLineRx stock in just a few minutes.

Fact checked

BioLineRx Ltd is a biotechnology business based in the US. BioLineRx shares (BLRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioLineRx employs 42 staff and has a market cap (total outstanding shares value) of USD$59.4 million.

How to buy shares in BioLineRx

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for BioLineRx. Find the stock by name or ticker symbol: BLRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioLineRx reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.92, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BioLineRx, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of BioLineRx. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

BioLineRx share price

Use our graph to track the performance of BLRX stocks over time.

BioLineRx shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$2.92
52-week rangeUSD$1.0609 - USD$3.3
50-day moving average USD$2.4855
200-day moving average USD$1.9903
Wall St. target priceUSD$12.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.835

Buy BioLineRx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BioLineRx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioLineRx price performance over time

Historical closes compared with the close of $2.92 from 2021-01-11

1 week (2021-01-12) 3.55%
1 month (2020-12-18) 11.03%
3 months (2020-10-19) 84.81%
6 months (2020-07-17) 60.44%
1 year (2020-01-17) 17.74%
2 years (2019-01-18) 403.45%
3 years (2018-01-19) 167.89%
5 years (2016-01-19) 207.37%

Is BioLineRx under- or over-valued?

Valuing BioLineRx stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioLineRx's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioLineRx's PEG ratio

BioLineRx's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioLineRx's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

BioLineRx financials

Gross profit TTM USD$0
Return on assets TTM -32.04%
Return on equity TTM -87.18%
Profit margin 0%
Book value $1.26
Market capitalisation USD$59.4 million

TTM: trailing 12 months

Shorting BioLineRx shares

There are currently 2.5 million BioLineRx shares held short by investors – that's known as BioLineRx's "short interest". This figure is 11.3% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting BioLineRx shares can be evaluated.

BioLineRx's "short interest ratio" (SIR)

BioLineRx's "short interest ratio" (SIR) is the quantity of BioLineRx shares currently shorted divided by the average quantity of BioLineRx shares traded daily (recently around 1.7 million). BioLineRx's SIR currently stands at 1.45. In other words for every 100,000 BioLineRx shares traded daily on the market, roughly 1450 shares are currently held short.

However BioLineRx's short interest can also be evaluated against the total number of BioLineRx shares, or, against the total number of tradable BioLineRx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioLineRx's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 BioLineRx shares in existence, roughly 110 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BioLineRx shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioLineRx.

Find out more about how you can short BioLineRx stock.

BioLineRx share dividends

We're not expecting BioLineRx to pay a dividend over the next 12 months.

Have BioLineRx's shares ever split?

BioLineRx's shares were split on a 1:15 basis on 15 July 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioLineRx shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for BioLineRx shares which in turn could have impacted BioLineRx's share price.

BioLineRx share price volatility

Over the last 12 months, BioLineRx's shares have ranged in value from as little as $1.0609 up to $3.3. A popular way to gauge a stock's volatility is its "beta".

BLRX.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioLineRx's is 1.4056. This would suggest that BioLineRx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

BioLineRx overview

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site